Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics

Changsu Han, Bun Hee Lee, Yong Ku Kim, Heon-Jeong Lee, Seung Hyun Kim, Leen Kim, Min-Soo Lee, Sook Haeng Joe, Byung-Joo Ham, In Kwa Jung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The satisfaction of schizophrenia patients with their treatment can strongly influence treatment adherence and subsequent long-term outcome. Atypical antipsychotics reportedly have greater adherence rates, owing to a lower incidence of side effects and higher levels of patient satisfaction and acceptability. However, patient satisfaction with long-acting injectable atypical antipsychotics has not been compared with that of oral atypical antipsychotics. Objective: The objective of the study was to identify differences in patient and caregiver satisfaction between long-acting injectable risperidone and oral atypical antipsychotics. Research design and methods: Forty-seven patients with schizophrenia, who were currently receiving treatment with long-acting injectable risperidone and their caregivers were surveyed using a semi-structured questionnaire that addressed their drug satisfaction and acceptability. Sixty-two patients currently taking oral atypical antipsychotics and their caregivers were surveyed for comparison. In the questionnaire, subjects were asked to indicate their satisfaction level on a 10-point visual analogue scale (VAS). Items to identify discomfort and side effects experienced were also included. Results: The VAS satisfaction score was significantly higher for patients receiving long-acting injectable risperidone than for those taking oral atypical antipsychotics (7.53 vs 6.87, P < 0.05). The overall VAS score was significantly higher for caregivers of both groups of patients than for the patients themselves (8.04 vs 7.16, P < 0.000). Conclusion: A new drug delivery system using long-acting injectable risperidone may offer better adherence in schizophrenia treatment, owing to higher levels of patient and caregiver satisfaction, and thereby result in improved treatment outcomes. Further studies in a strictly controlled setting are strongly needed because that present study was not strictly controlled and the duration of treatment of the injection group was relatively short.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalPrimary Care and Community Psychiatry
Volume10
Issue number3
DOIs
Publication statusPublished - 2005 Dec 1

Fingerprint

Risperidone
Patient Satisfaction
Caregivers
Antipsychotic Agents
Injections
Visual Analog Scale
Schizophrenia
Therapeutics
Drug Delivery Systems
Research Design
Incidence
Pharmaceutical Preparations

Keywords

  • Atypical
  • Depot
  • Long-acting injectable risperidone
  • Satisfaction

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. / Han, Changsu; Lee, Bun Hee; Kim, Yong Ku; Lee, Heon-Jeong; Kim, Seung Hyun; Kim, Leen; Lee, Min-Soo; Joe, Sook Haeng; Ham, Byung-Joo; Jung, In Kwa.

In: Primary Care and Community Psychiatry, Vol. 10, No. 3, 01.12.2005, p. 119-124.

Research output: Contribution to journalArticle

@article{db140fd105ed4c2cb26d5dfa7b5ba221,
title = "Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics",
abstract = "Background: The satisfaction of schizophrenia patients with their treatment can strongly influence treatment adherence and subsequent long-term outcome. Atypical antipsychotics reportedly have greater adherence rates, owing to a lower incidence of side effects and higher levels of patient satisfaction and acceptability. However, patient satisfaction with long-acting injectable atypical antipsychotics has not been compared with that of oral atypical antipsychotics. Objective: The objective of the study was to identify differences in patient and caregiver satisfaction between long-acting injectable risperidone and oral atypical antipsychotics. Research design and methods: Forty-seven patients with schizophrenia, who were currently receiving treatment with long-acting injectable risperidone and their caregivers were surveyed using a semi-structured questionnaire that addressed their drug satisfaction and acceptability. Sixty-two patients currently taking oral atypical antipsychotics and their caregivers were surveyed for comparison. In the questionnaire, subjects were asked to indicate their satisfaction level on a 10-point visual analogue scale (VAS). Items to identify discomfort and side effects experienced were also included. Results: The VAS satisfaction score was significantly higher for patients receiving long-acting injectable risperidone than for those taking oral atypical antipsychotics (7.53 vs 6.87, P < 0.05). The overall VAS score was significantly higher for caregivers of both groups of patients than for the patients themselves (8.04 vs 7.16, P < 0.000). Conclusion: A new drug delivery system using long-acting injectable risperidone may offer better adherence in schizophrenia treatment, owing to higher levels of patient and caregiver satisfaction, and thereby result in improved treatment outcomes. Further studies in a strictly controlled setting are strongly needed because that present study was not strictly controlled and the duration of treatment of the injection group was relatively short.",
keywords = "Atypical, Depot, Long-acting injectable risperidone, Satisfaction",
author = "Changsu Han and Lee, {Bun Hee} and Kim, {Yong Ku} and Heon-Jeong Lee and Kim, {Seung Hyun} and Leen Kim and Min-Soo Lee and Joe, {Sook Haeng} and Byung-Joo Ham and Jung, {In Kwa}",
year = "2005",
month = "12",
day = "1",
doi = "10.1185/135525706X75267",
language = "English",
volume = "10",
pages = "119--124",
journal = "Primary Care and Community Psychiatry",
issn = "1746-8841",
publisher = "Librapharm",
number = "3",

}

TY - JOUR

T1 - Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics

AU - Han, Changsu

AU - Lee, Bun Hee

AU - Kim, Yong Ku

AU - Lee, Heon-Jeong

AU - Kim, Seung Hyun

AU - Kim, Leen

AU - Lee, Min-Soo

AU - Joe, Sook Haeng

AU - Ham, Byung-Joo

AU - Jung, In Kwa

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Background: The satisfaction of schizophrenia patients with their treatment can strongly influence treatment adherence and subsequent long-term outcome. Atypical antipsychotics reportedly have greater adherence rates, owing to a lower incidence of side effects and higher levels of patient satisfaction and acceptability. However, patient satisfaction with long-acting injectable atypical antipsychotics has not been compared with that of oral atypical antipsychotics. Objective: The objective of the study was to identify differences in patient and caregiver satisfaction between long-acting injectable risperidone and oral atypical antipsychotics. Research design and methods: Forty-seven patients with schizophrenia, who were currently receiving treatment with long-acting injectable risperidone and their caregivers were surveyed using a semi-structured questionnaire that addressed their drug satisfaction and acceptability. Sixty-two patients currently taking oral atypical antipsychotics and their caregivers were surveyed for comparison. In the questionnaire, subjects were asked to indicate their satisfaction level on a 10-point visual analogue scale (VAS). Items to identify discomfort and side effects experienced were also included. Results: The VAS satisfaction score was significantly higher for patients receiving long-acting injectable risperidone than for those taking oral atypical antipsychotics (7.53 vs 6.87, P < 0.05). The overall VAS score was significantly higher for caregivers of both groups of patients than for the patients themselves (8.04 vs 7.16, P < 0.000). Conclusion: A new drug delivery system using long-acting injectable risperidone may offer better adherence in schizophrenia treatment, owing to higher levels of patient and caregiver satisfaction, and thereby result in improved treatment outcomes. Further studies in a strictly controlled setting are strongly needed because that present study was not strictly controlled and the duration of treatment of the injection group was relatively short.

AB - Background: The satisfaction of schizophrenia patients with their treatment can strongly influence treatment adherence and subsequent long-term outcome. Atypical antipsychotics reportedly have greater adherence rates, owing to a lower incidence of side effects and higher levels of patient satisfaction and acceptability. However, patient satisfaction with long-acting injectable atypical antipsychotics has not been compared with that of oral atypical antipsychotics. Objective: The objective of the study was to identify differences in patient and caregiver satisfaction between long-acting injectable risperidone and oral atypical antipsychotics. Research design and methods: Forty-seven patients with schizophrenia, who were currently receiving treatment with long-acting injectable risperidone and their caregivers were surveyed using a semi-structured questionnaire that addressed their drug satisfaction and acceptability. Sixty-two patients currently taking oral atypical antipsychotics and their caregivers were surveyed for comparison. In the questionnaire, subjects were asked to indicate their satisfaction level on a 10-point visual analogue scale (VAS). Items to identify discomfort and side effects experienced were also included. Results: The VAS satisfaction score was significantly higher for patients receiving long-acting injectable risperidone than for those taking oral atypical antipsychotics (7.53 vs 6.87, P < 0.05). The overall VAS score was significantly higher for caregivers of both groups of patients than for the patients themselves (8.04 vs 7.16, P < 0.000). Conclusion: A new drug delivery system using long-acting injectable risperidone may offer better adherence in schizophrenia treatment, owing to higher levels of patient and caregiver satisfaction, and thereby result in improved treatment outcomes. Further studies in a strictly controlled setting are strongly needed because that present study was not strictly controlled and the duration of treatment of the injection group was relatively short.

KW - Atypical

KW - Depot

KW - Long-acting injectable risperidone

KW - Satisfaction

UR - http://www.scopus.com/inward/record.url?scp=33644828783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644828783&partnerID=8YFLogxK

U2 - 10.1185/135525706X75267

DO - 10.1185/135525706X75267

M3 - Article

VL - 10

SP - 119

EP - 124

JO - Primary Care and Community Psychiatry

JF - Primary Care and Community Psychiatry

SN - 1746-8841

IS - 3

ER -